As of October 22, 2026, Sagimet Biosciences Inc. Series A Common Stock (SGMT) trades at $9.95. Equity Rank's blended estimate across 2 valuation models with sufficient data is $8.33 — a model fair value differential of 16.3% below the current price under these model assumptions. Model-derived estimate, informational only — not investment advice.
Source: Equity Rank — SGMT fair value (data as of 2026-10-22). The full page adds the per-method breakdown and the model’s scenario range (with an Equity Rank account).
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is next scheduled to report earnings on Nov 12, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.25.
Heading into this report, the model's fair value estimate sits 16.3% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Reported EPS came in above the analyst estimate in 6 of the last 8 reports. The median share-price change across a report, in either direction, was 3.6%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.28 | $-0.26 | +7.1% | -0.5% |
| May 12, 2026 | $-0.35 | $-0.33 | +5.7% | -0.5% |
| Mar 11, 2026 | $-0.40 | $-0.29 | +27.8% | +3.8% |
| Nov 13, 2025 | $-0.39 | $-0.40 | -2.6% | -12.2% |
| Aug 13, 2025 | $-0.50 | $-0.32 | +36.0% | +0.3% |
| May 8, 2025 | $-0.71 | $-0.56 | +21.1% | -4.2% |
| Mar 12, 2025 | $-0.65 | $-0.50 | +23.1% | +3.4% |
| Nov 14, 2024 | $-0.40 | $-0.45 | -12.5% | -13.9% |
Equity Rank computed model fair value for SGMT from 2 independent valuation methods with sufficient data. 0 place fair value above the current price of $9.95, and 2 place it below. The model-blended estimate lands at $8.33 — a model fair value differential of 16.3% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores SGMT at 38.5/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved +0.3 over the past 30 days.
Equity Rank's intrinsic value estimate for Sagimet Biosciences Inc. Series A Common Stock (SGMT) — the model fair value — is $8.33 as of October 22, 2026, blended from 2 valuation methods with sufficient data. An intrinsic value estimate is what the models compute a share to be worth under stated assumptions; it is not a price target, not a prediction of where the stock will trade, and not investment advice.
Equity Rank calculates fair value for SGMT by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/SGMT. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.